Zhongbo Juli

The company has many years of experience in investment consulting for central enterprises, and has super soft investment power.

Kang Yaoyun

Chairman

13 past transactions

Null Hypothesis

Series B in 2024
Null Hypothesis is an AI medical software-as-a-service company dedicated to creating intelligent medical products that enhance the commercialization of innovative drugs. By integrating advanced data technology with medical expertise, Null Hypothesis aims to streamline the knowledge transfer process within the academic promotion chain. This approach fosters a more efficient and professional exchange of information, ultimately supporting advancements in the medical field.

Shenji Changhua

Seed Round in 2024
Shenji Changhua is a biotechnology company focusing on neurological diseases such as ALS.

Binhui Biotech

Series C in 2024
Wuhan Binhui Biotechnology Co., Ltd., established in 2010 and headquartered in Wuhan, China, specializes in the development of virus injection preparations. Situated in the Optics Valley Bio City within the Donghu National Independent Innovation Demonstration Zone, the company focuses on creating innovative products and services in the oncology sector, encompassing both diagnosis and treatment. Binhui Biotech is dedicated to developing offerings with independent intellectual property rights, aiming to compete effectively on the international market.

HemaCell

Series A in 2023
HemaCell is a cell therapy company specializing in the in vitro regeneration of hematopoietic lineages, including blood and immune cells. Founded by experts with extensive experience in the field, the company utilizes advanced stem cell reprogramming and differentiation technologies to develop innovative solutions. HemaCell is focused on addressing the pressing demand for platelets in the treatment of various conditions, such as cancer, liver disease, critical illnesses, and hematological disorders. Additionally, the company is dedicated to creating new therapeutic drugs targeting diseases associated with platelet abnormalities, thereby offering effective treatment options for patients.

Linkwise Technology

Series A in 2023
Linkwise Technology is a semiconductor company specializing in automation solutions for semiconductor production line logistics. The firm develops customized semiconductor packaging and testing technologies, focusing primarily on automated material handling systems (AMHS). Its services encompass planning and designing automation systems for semiconductor production, producing automatic logistics handling equipment, and developing software control systems. Additionally, Linkwise Technology aids in the intelligent transformation of production equipment and processes. Through these innovations, the company enables its clients to enhance manufacturing efficiency by saving labor costs, optimizing processes, improving product yields, and reducing overall production expenses.

Zenosic

Series A in 2023
Zenosic focuses in the design and R&D of high-performance network chips, along with offering leading chip products for cloud service providers, equipment makers, operators, and diverse industries.

Innolake Biopharm

Series A in 2023
Innolake Biopharm is a clinical-stage biotechnology company specializing in the development of therapeutic drugs aimed at treating oncology and autoimmune diseases. The company is actively engaged in research and development, focusing on innovative solutions to address tumors and immune system disorders. With an extensive product development pipeline, Innolake Biopharm seeks to improve patient health outcomes by delivering advanced treatment options.

Boruspan Precision

Series D in 2023
Boruspan is a machine tool manufacturing enterprise, engaged in the R&D and manufacturing of high-precision CNC machine tools.

Immunophage Biotech

Series B in 2023
Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.

Enze Kangtai

Series A in 2023
Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research.

Picocom

Series C in 2022
Picocom specializes in the development of semiconductor products and software for 5G small cell infrastructure, focusing on open radio access network (RAN) standards. The company designs and markets baseband system-on-chips (SoCs) and carrier-grade software solutions that comply with Open RAN standards. By providing these advanced technologies, Picocom aims to enhance the capabilities of 5G networks, offering industry users innovative system and chip solutions tailored for small cell applications.

Microchain Vision

Series A in 2021
Welink Vision is a 3D robot vision technology developer, focused on the R&D of cognitive robots, and integration of IT and RT technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.